Regulatory Exclusivity Expiring in 2029
✉ Email this page to a colleague
Drugs with Regulatory Exclusivity Expiring in 2029
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|
Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try for Free | NEW CHEMICAL ENTITY | |
Gilead Sciences Inc | DESCOVY | emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 208215-002 | Jan 7, 2022 | RX | Yes | No | ⤷ Try for Free | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 14 KG TO LESS THAN 25 KG | |
Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-001 | Feb 17, 2022 | RX | Yes | No | ⤷ Try for Free | TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY | |
Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-002 | Feb 17, 2022 | RX | Yes | No | ⤷ Try for Free | TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY | |
Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-003 | Feb 17, 2022 | RX | Yes | Yes | ⤷ Try for Free | TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY | |
Allecra Theraps | EXBLIFEP | cefepime hydrochloride; enmetazobactam | POWDER;INTRAVENOUS | 216165-001 | Feb 22, 2024 | DISCN | Yes | No | ⤷ Try for Free | NEW CHEMICAL ENTITY | |
Sobi | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try for Free | TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |